Home » NASTECH PHARMA ENTERS DEVELOPMENT DEAL WITH AMYLIN PHARMA

NASTECH PHARMA ENTERS DEVELOPMENT DEAL WITH AMYLIN PHARMA

June 26, 2006

Nastech Pharmaceutical Company Inc. entered a agreement with Amylin Pharmaceuticals, Inc. to develop a nasal spray formulation of exenatide. StreetInsider.com (http://www.streetinsider.com/news.php?id=988986&st=p)

KEYWORDS FDAnews Drug Daily Bulletin

19Jan
Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management
21Jan
Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits
26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

NASTECH PHARMA ENTERS DEVELOPMENT DEAL WITH AMYLIN PHARMA

Upcoming Events

Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

Medical Device Clinical Trials in China: Latest Regulatory Developments

FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements